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Sales of medicines in the field and the vital interests of the people closely 
related to commercial bribery has become the hardest hit, thus increasing the mass 
medical care difficult and expensive problems, causing confusion in medical 
management, patient relations, medical malpractice by the phenomenon. 
Pharmaceutical purchasing commercial bribery exist in the field, not only ruined the 
health industry and the image of medical staff, also contributed to the current one 
important reason to hold down prices, directly affecting the health and healthy 
development. If not control the field of commercial bribery, drug sales resulting from 
medical corruption, will give the Chinese economy a serious injury, construction of 
harmonious society. Therefore, how to combat commercial bribery in the medical 
field has been the legal circles and the medical profession one of the topics 
discussed. 
In view of this, the article combines the purchase and sale of foreign and 
Chinese medicine in the field of crime legislation and practice of commercial bribery 
cases, to improve the field of pharmaceuticals purchasing commercial bribery 
legislation and suggestions. 
Full-text including introduction, body and conclusion of three parts. Text is 
divided into four chapters: 
The first chapter is the field of medicine buying and selling commercial bribery 
overview of related content, including the purchase and sale of 
pharmaceutical-related areas of commercial bribery definition of the concept, the 
field of medicine purchase and sale of the causes of commercial bribery. 
The second chapter describes the field of medicine purchase and sale of 
commercial bribery investigation of extraterritorial legislation, including 
anti-commercial bribery in the field of pharmaceutical procurement status of 
legislation, the characteristics of anti-commercial bribery legislation. 
The third chapter is the field of pharmaceutical procurement bribery as defined 
by an overview of related content, including the crime of bribery object, the behavior 
of commercial bribery and commercial bribery in the "kickbacks" and "red" and 














Chapter IV with "United Nations Convention against Corruption" to discuss the 
provisions of purchase and sale of perfecting the field of anti-commercial bribery 
medical status of legislation. 
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前  言 
 1
前  言 
2005 年 5 月,美国 Diagnostic Products Corporation(简称 DPC)公司和美国司
法部同时宣布，因该公司在中国天津的子公司——天津德普诊断产品有限公司通
过商业贿赂取得中国医院的订单，而被罚款 479 万美元。美国司法部提供的数据
显示，天津德普诊断产品有限公司从 1991 年到 2002 年期间，向中国医院医生行
贿 162.3 万美元，用来换取这些医疗机构购买 DPC 的产品，德普公司从中赚取





















                                                        
①卫生部公布治理医药购销商业贿赂五大重点中国新闻网[EB/OL]. 
http//www.sina.com.cn/news-hot/2006 年 3 月 28 日,2006-3-28. 















第一章  医药购销领域商业贿赂犯罪概述 

















































正式的法律术语适用第一次出现在 1996 年 11 月 15 日的国家工商行政管理局颁
布的《关于禁止商业贿赂行为的暂行规定》（以下简称《暂行规定》）中。该法
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